Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

• Status: Recruiting
• Trial end date: 2023-10-09
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimen for newly diagnosed advanced extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Asparaginase; Gemcitabine; Oxaliplatin; Pegaspargase

Criteria

Inclusion Criteria:

• biopsy proved extranodal natural killer/T-cell lymphoma, nasal type;

• newly diagnosed stage III/IV patients;

• at least one evaluable lesion；

• ECOG PS 0-2;

• 18-75 years; without other malignancy;

• proper functioning of the major organs.

Exclusion Criteria:

• hemophagocytic syndrome or aggressive NK cell leukemia;

• involvement of central nervous system;

• previously received treatment of chemotherapy, radiotherapy, immunotherapy or biotherapy for lymphoma；